Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX)
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
03:39pm, Thursday, 20'th Feb 2025
LOS ANGELES , Feb. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX)
The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation
11:00am, Thursday, 20'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant T
An Investigation Has Commenced on Behalf of Pliant Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PLRX Losses
10:30am, Thursday, 20'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX)
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation
10:00am, Thursday, 20'th Feb 2025
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Co
Did Pliant Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PLRX
03:00pm, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
02:30pm, Wednesday, 19'th Feb 2025
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such inves
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pliant Therapeutics, Inc. (PLRX) Regarding Possible Securities Fraud Violations
12:15pm, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX)
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant T
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pliant Therapeutics, Inc. (PLRX) Regarding Possible Securities Fraud Violations
10:15am, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX)
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Co
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX)
NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:
The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation
07:15pm, Tuesday, 18'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant T
